RecruitingNot ApplicableNCT06216665

Effect of Pulsatile Hormone Administration on Insulin Action


Sponsor

Pennington Biomedical Research Center

Enrollment

12 participants

Start Date

Mar 4, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

In humans, insulin is secreted in pulses from the pancreatic beta-cells, and these oscillations help to maintain fasting plasma glucose levels within a narrow normal range. Given the fluctuations in insulin concentrations, oscillations enhance precision of control. The hyperinsulinemic euglycemic clamp test (clamp) involves a continuous infusion of insulin and is the gold standard for measuring insulin sensitivity. In this study, insulin sensitivity measured using the standard clamp will be compared with a clamp in which the same total amount of insulin as the standard clamp is infused every five minutes instead of continuously.


Eligibility

Min Age: 50 YearsMax Age: 75 Years

Inclusion Criteria1

  • Completion of the Motivate Study (NCT05649176)

Exclusion Criteria1

  • Non-completion of the end-of-study hyperinsulinemic euglycemic clamp test of the Motivate study

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERContinuous Insulin administration during hyperinsulinemic euglycemic clamp test

Participants will receive insulin delivered continuously during the hyperinsulinemic euglycemic clamp test

OTHERPulsatile Insulin administration during hyperinsulinemic euglycemic clamp test

Participants will receive insulin delivered every five minutes during the hyperinsulinemic euglycemic clamp test


Locations(1)

Pennington Biomedical Research Center

Baton Rouge, Louisiana, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06216665


Related Trials